# Angela Dispenzieri

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/angela-dispenzieri/

## Facts

| Field | Value |
| --- | --- |
| Citations | 101,013 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 147 |
| i10-index | 879 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5000308170 |
| ORCID iD | https://orcid.org/0000-0001-8780-9512 |
| Works | 2,492 |

## Researcher papers

- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease](https://scholariq.org/papers/international-evidence-based-consensus-diagnostic-criteria-for-hhv-8-negative/)
- [The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group](https://scholariq.org/papers/the-evaluation-of-monoclonal-gammopathy-of-renal-significance-a-consensus-report/)
- [Genotype and Phenotype of Transthyretin Cardiac Amyloidosis](https://scholariq.org/papers/genotype-and-phenotype-of-transthyretin-cardiac-amyloidosis/)
- [Diagnosis of monoclonal gammopathy of renal significance](https://scholariq.org/papers/diagnosis-of-monoclonal-gammopathy-of-renal-significance/)
- [International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease](https://scholariq.org/papers/international-evidence-based-consensus-treatment-guidelines-for-idiopathic/)
- [International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease](https://scholariq.org/papers/international-evidence-based-consensus-diagnostic-and-treatment-guidelines-for/)
- [Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study](https://scholariq.org/papers/long-term-safety-and-efficacy-of-patisiran-for-hereditary-transthyretin-mediated/)
- [International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation](https://scholariq.org/papers/international-myeloma-working-group-guidelines-for-the-management-of-multiple/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Amyloidosis: Diagnosis, Treatment, Outcomes](https://scholariq.org/topics/amyloidosis-diagnosis-treatment-outcomes/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.